Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

etranacogene dezaparvovec (Hemgenix)

Therapeutic Area: Hemophilia B
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

infliximab (Remsima)

Therapeutic Area: Crohn’s disease
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 05, 2024
Draft Recommendation
 

Submit Feedback

 

infliximab (Remsima)

Therapeutic Area: Ulcerative Colitis
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 05, 2024
Draft Recommendation
 

Submit Feedback

 

maralixibat (Livmarli)

Therapeutic Area: Alagille syndrome
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

cannabidiol (Epidiolex)

Therapeutic Area: Seizures associated with Tuberous Sclerosis Complex (TSC)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

cannabidiol (Epidiolex)

Therapeutic Area: Dravet Syndrome (DS)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

cannabidiol (Epidiolex)

Therapeutic Area: Lennox-Gastaut Syndrome (LGS)
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

inclisiran (Leqvio)

Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

inclisiran (Leqvio)

Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: March 21, 2024
End of feedback period: April 5, 2024
Draft Recommendation
 

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: ALK-positive NSCLC
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Gastrointestinal cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Pulmonary arterial hypertension (WHO group 1)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Paroxysmal nocturnal hemoglobinuria (PNH)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Acute myeloid leukemia (AML)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Clostridium difficile infection
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: